Treatment response in patients with clinical and supportive laboratory features of chronic inflammatory demyelinating polyneuropathy without demyelinative findings on nerve conduction studies: A retrospective study
Muscle & Nerve · 2024
DOI: 10.1002/mus.28198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2024. Verfasst von Patrick Curry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Neural Conduction, Magnetic Resonance Imaging. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Introduction/Aims Not all patients with chronic inflammatory demyelinating polyneuropathy (CIDP) have evidence of demyelination on nerve conduction studies (NCS). Patients with “supportive” evidence of CIDP on cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), ultrasound (US), or nerve biopsy but not on NCS, often receive immunomodulating therapy. We evaluated the treatment response of patients with clinical and supportive features of CIDP lacking NCS evidence of demyelination.
Methods
Retrospective chart review was conducted on 232 patients who met CIDP clinical criteria and were treated with disease‐modifying therapy. Patients included did not have NCS criteria of demyelination, but did have supportive CSF, MRI, or US findings consistent with CIDP. A positive treatment response was defined as at least a one‐point improvement in the modified Rankin scale (mRS), or a four‐point increase in the Medical Research Council sum score (MRCSS).
Results
Twenty patients met criteria: 17 of the 18 (94%) patients with CSF protein >45 mg/dL, 6 of the 14 (43%) with MRI lumbosacral root or plexus enhancement, and 4 of the 6 (67%) with enlarged proximal nerves on US. Eighteen patients received intravenous immunoglobulin, 10 corticosteroids, one plasma exchange, and six other immunomodulatory therapies. Twelve patients had a positive treatment response on the MRCSS or mRS. The presence of MRI lumbosacral root or plexus enhancement was associated with a positive treatment response.
Discussion
A trial of immunomodulating treatment should be considered for patients with clinical features of CIDP in the absence of NCS evidence of demyelination, particularly when there is MRI lumbosacral root or plexus enhancement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
- Biostatistics Core, Arkansas Children's Research Institute, Little Rock, Arkansas, USA.
ORCID-Profile: Patrick Curry, Chary Akmyradov, Eric Logigian
Zitieren
APA
Curry, P., Herrmann, D. N., Stanton, M., Mongiovi, P., Akmyradov, C., & Logigian, E. (2024). Treatment response in patients with clinical and supportive laboratory features of chronic inflammatory demyelinating polyneuropathy without demyelinative findings on nerve conduction studies: A retrospective study. Muscle & Nerve. https://doi.org/10.1002/mus.28198
Vancouver
Curry P, Herrmann DN, Stanton M, Mongiovi P, Akmyradov C, Logigian E. Treatment response in patients with clinical and supportive laboratory features of chronic inflammatory demyelinating polyneuropathy without demyelinative findings on nerve conduction studies: A retrospective study. Muscle & Nerve. 2024. doi:10.1002/mus.28198
BibTeX
@article{Curry2024,
author = {Curry, Patrick and Herrmann, David N and Stanton, Michael and Mongiovi, Phillip and Akmyradov, Chary and Logigian, Eric},
title = {Treatment response in patients with clinical and supportive laboratory features of chronic inflammatory demyelinating polyneuropathy without demyelinative findings on nerve conduction studies: A retrospective study},
journal = {Muscle & Nerve},
year = {2024},
doi = {10.1002/mus.28198}
}
EUVIMED